Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease

Benchimol, 2011, Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends, Inflamm Bowel Dis., 17, 423, 10.1002/ibd.21349 Kappelman, 2007, The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States, Clin Gastroenterol Hepatol, 5, 1424, 10.1016/j.cgh.2007.07.012 Polito II, 1996, Crohn's disease: influence of age at diagnosis on site and clinical type of disease, Gastroenterology, 111, 580, 10.1053/gast.1996.v111.pm8780560 Griffiths, 2004, Specificitiesofinflammatoryboweldiseaseinchildhood, BestPractResClinGastroenterol, 18, 509 Van Limbergen, 2008, Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease, Gastroenterology, 135, 1114, 10.1053/j.gastro.2008.06.081 Vernier-Massouille, 2008, Natural history of pediatric Crohn's disease: a population-based cohort study, Gastroenterology, 135, 1106, 10.1053/j.gastro.2008.06.079 Pigneur, 2010, Natural history of Crohn's disease: comparison between childhood- and adult-onset disease, Inflamm Bowel Dis, 16, 953, 10.1002/ibd.21152 D’Haens, 2008, Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, Lancet, 371, 660, 10.1016/S0140-6736(08)60304-9 Neurath, 2012, Mucosal healing in inflammatory bowel diseases: a systematic review, Gut, 61, 1619, 10.1136/gutjnl-2012-302830 Rismo, 2012, The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease, Scand J Gastroenterol, 47, 1200, 10.3109/00365521.2012.711853 Kierkus, 2012, The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease, Eur J Gastroenterol Hepatol, 24, 495, 10.1097/MEG.0b013e32835159f2 Laharie, 2011, Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab, Aliment Pharmacol Ther, 33, 714, 10.1111/j.1365-2036.2010.04569.x Baert, 2010, Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease, Gastro-enterology, 138, 463, 10.1053/j.gastro.2009.09.056 Pariente, 2011, Development of the Crohn's disease digestive damage score, the Lemann score, Inflamm Bowel Dis, 17, 1415, 10.1002/ibd.21506 Rimola, 2011, Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity, Inflamm Bowel Dis, 17, 1759, 10.1002/ibd.21551 Sipponen, 2008, Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings, Aliment Pharmacol Ther, 28, 1221, 10.1111/j.1365-2036.2008.03835.x Walters, 2009, Mechanisms of growth impairment in pediatric Crohn's disease, Nat Rev Gastroenterol Hepatol, 6, 513, 10.1038/nrgastro.2009.124 Bailey, 1997, The Saskatchewan pediatric bone mineral accrual study: bone mineral acquisition during the growing years, Int J Sports Med, 18, S191, 10.1055/s-2007-972713 Pfefferkorn, 2009, Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms, J Pediatr Gastroenterol Nutr, 48, 168, 10.1097/MPG.0b013e318175ca7f Escher, 2004, Mucosal healing in pediatric Crohn's disease: pro/con balance, Inflamm Bowel Dis, 10, 484, 10.1097/00054725-200407000-00026 Bousvaros, 2004, Mucosal healing in children with Crohn's disease: appropriate therapeutic goal or medical overkill?, Inflamm Bowel Dis, 10, 481, 10.1097/00054725-200407000-00025 Beaugerie, 2006, Predictors of Crohn's disease, Gastroenterology, 130, 650, 10.1053/j.gastro.2005.12.019 Allez, 2002, Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy, Am J Gastroenterol, 97, 947 Cosnes, 2012, Factors affecting outcomes in Crohn's disease over 15 years, Gut, 61, 1140, 10.1136/gutjnl-2011-301971 Levine, 2013, The ESPGHAN Revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents, J Pediatr Gastroenterol Nutr, 10.1097/MPG.0000000000000239 Levine, 2011, Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification, Inflamm Bowel Dis, 17, 1314, 10.1002/ibd.21493 Zachos, 2007, Enteral nutritional therapy for induction of remission in Crohn's disease, Cochrane Database Syst Rev, 1, Cd000542 Heuschkel, 2000, Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children, J Pediatr Gastroenterol Nutr, 31, 8, 10.1097/00005176-200007000-00005 Dziechciarz, 2007, Meta-analysis: enteral nutrition in active Crohn's disease in children, Aliment Pharmacol Ther, 26, 795, 10.1111/j.1365-2036.2007.03431.x Thomas, 1993, Dietary intake and nutritional treatment in childhood Crohn's disease, J Pediatr Gastroenterol Nutr, 17, 75, 10.1097/00005176-199307000-00011 Sanderson, 1987, Remission induced by an elemental diet in small bowel Crohn's disease, Arch Dis Child, 62, 123, 10.1136/adc.62.2.123 Seidman, 1991, Elemental diet versus prednisone as initial therapy in Crohn's disease: early and long term results, Gastroenterology, 100, A250 Terrin, 2002, A semielemental diet (Pregomin) as pri- mary therapy for inducing remission in children with active Crohn’'s disease, Ital J Pediatr, 28, 401 Seidman, 1993, Semi-elemental (S-E) diet versus prednisone in pediatric Crohn's disease. Gastroenterology 1993, Gastroenterology, 104, A778 Ruuska, 1994, Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn's disease in children, J Pediatr Gastroenterol Nutr, 19, 175, 10.1097/00005176-199408000-00006 Borrelli, 2006, Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial, Clin Gastroenterol Hepatol, 4, 744, 10.1016/j.cgh.2006.03.010 Grogan, 2012, Enteral feeding therapy for newly diagnosed pediatric Crohn's disease: a double-blind randomized controlled trial with two years follow-up, Inflamm Bowel Dis, 18, 246, 10.1002/ibd.21690 Day, 2008, Systematic review: nutritional therapy in paediatric Crohn's disease, Aliment Pharmacol Ther, 27, 293, 10.1111/j.1365-2036.2007.03578.x Wilson, 2010, Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease, J Pediatr Gastroenterol Nutr, 50, S14, 10.1097/MPG.0b013e3181c92caa Teahon, 1995, Alterations in nutritional status and disease activity during treatment of Crohn's disease with elemental diet, Scand J Gastroenterol, 30, 54, 10.3109/00365529509093236 Bannerjee, 2004, Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease, J Pediatr Gastroenterol Nutr, 38, 270, 10.1097/00005176-200403000-00007 Buchanan, 2009, The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission, Aliment Pharmacol Ther, 30, 501, 10.1111/j.1365-2036.2009.04067.x Rubio, 2011, The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated oral vs, continuous enteral feeding. Aliment Pharmacol Ther, 33, 1332, 10.1111/j.1365-2036.2011.04662.x Johnson, 2006, Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial, Gut, 55, 356, 10.1136/gut.2004.062554 Akobeng, 2000, Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease, J Pediatr Gastroenterol Nutr, 30, 78, 10.1097/00005176-200001000-00022 Ludvigsson, 2004, Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial, Acta Paediatr, 93, 327, 10.1111/j.1651-2227.2004.tb02956.x Verma, 2000, Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial, Am J Gastroenterol, 95, 735, 10.1111/j.1572-0241.2000.01527.x Rodrigues, 2007, Does polymeric formula improve adherence to liquid diet therapy in children with active Crohn's disease?, Arch Dis Child, 92, 767, 10.1136/adc.2006.103416 Afzal, 2004, Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition, Aliment Pharmacol Ther, 20, 167, 10.1111/j.1365-2036.2004.02002.x Gailhoustet, 2002, Study of psychological repercussions of 2 modes of treatment of adolescents with Crohn's disease, Arch Pediatr, 9, 110, 10.1016/S0929-693X(01)00717-5 Critch, 2012, Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease, J Pediatr Gastroenterol Nutr, 54, 298, 10.1097/MPG.0b013e318235b397 Whitten, 2012, International survey of enteral nutrition protocols used in children with Crohn's disease, J Dig Dis, 13, 107, 10.1111/j.1751-2980.2011.00558.x Fell, 2000, Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease, Aliment Pharmacol Ther, 14, 281, 10.1046/j.1365-2036.2000.00707.x Afzal, 2005, Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved, Dig Dis Sci, 50, 1471, 10.1007/s10620-005-2864-6 Knight, 2005, Long-term outcome of nutritional therapy in paediatric Crohn's disease, Clin Nutr, 24, 775, 10.1016/j.clnu.2005.03.005 Day, 2006, Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach, J Gastroenterol Hepatol, 21, 1609, 10.1111/j.1440-1746.2006.04294.x Berni Canani, 2006, Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease, Dig Liver Dis, 38, 381, 10.1016/j.dld.2005.10.005 Beattie, 1994, Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease, Aliment Pharmacol Ther, 8, 609, 10.1111/j.1365-2036.1994.tb00338.x Cameron, 2013, Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease, Aliment Pharmacol Ther, 37, 622, 10.1111/apt.12230 Turner, 2012, Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines, J Pediatr Gastroenterol Nutr, 55, 340, 10.1097/MPG.0b013e3182662233 Ford, 2011, Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis, Am J Gastroenterol, 106, 590, 10.1038/ajg.2011.70 Escher, 2004, Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial, Eur J Gastroenterol Hepatol, 16, 47, 10.1097/00042737-200401000-00008 Levine, 2003, A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease, J Pediatr Gastroenterol Nutr, 36, 248, 10.1097/00005176-200302000-00017 Markowitz, 2000, A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease, Gastroenter-ology, 119, 895, 10.1053/gast.2000.18144 Tung, 2006, A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis, Inflamm Bowel Dis, 12, 1093, 10.1097/01.mib.0000235835.32176.85 Sidoroff, 2012, Glucocorticoids in pediatric inflammatory bowel disease, Scand J Gastroenterol, 47, 745, 10.3109/00365521.2012.679681 Byron, 1983, Effect of different corticosteroid regimens on hypothalamic-pituitary-adrenal axis and growth in juvenile chronic arthritis, J R Soc Med, 76, 452, 10.1177/014107688307600604 Shepherd, 1986, Use of an intravenous steroid regimen in the treatment of acute Crohn's disease, J Clin Gastroenterol, 8, 154, 10.1097/00004836-198604000-00010 Sandhu, 2010, Guidelines for the management of inflammatory bowel disease in children in the United Kingdom, J Pediatr Gastroenterol Nutr, 50, S1, 10.1097/MPG.0b013e3181c92c53 Modigliani, 1990, Clinical, biological, and endoscopic picture of attacks of Crohn's disease, Evolution on prednisolone Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology, 98, 811 Olaison, 1990, Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation, Gut, 31, 325, 10.1136/gut.31.3.325 Mantzaris, 2009, Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease, Inflamm Bowel Dis, 15, 375, 10.1002/ibd.20777 Markowitz, 2006, Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease, Clin Gastroenterol Hepatol, 4, 1124, 10.1016/j.cgh.2006.05.011 Kolho, 2006, Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease, Scand J Gastroenterol, 41, 720, 10.1080/00365520500419623 Jakobsen, 2011, Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators—a population-based study, Inflamm Bowel Dis, 17, 1731, 10.1002/ibd.21559 Levine, 2002, Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children, J Pediatr, 140, 75, 10.1067/mpd.2002.119992 Seow, 2008, Budesonide for induction of remission in Crohn's disease, Cochrane Database Syst Rev, 3, Cd000296 Nunes, 2013, Oral locally active steroids in inflammatory bowel disease, J Crohns Colitis, 7, 183, 10.1016/j.crohns.2012.06.010 De Cassan, 2012, Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?, Dig Dis, 30, 368, 10.1159/000338128 Levine, 2009, Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial, Inflamm Bowel Dis, 15, 1055, 10.1002/ibd.20881 Dignass, 2010, The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management, J Crohns Colitis, 4, 28, 10.1016/j.crohns.2009.12.002 Dilger, 2006, Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease, Aliment Pharmacol Ther, 23, 387, 10.1111/j.1365-2036.2006.02771.x Huscher, 2009, Dose-related patterns of glucocorticoid-induced side effects, Ann Rheum Dis, 68, 1119, 10.1136/ard.2008.092163 Schacke, 2002, Mechanisms involved in the side effects of glucocorticoids, Pharmacol Ther, 96, 23, 10.1016/S0163-7258(02)00297-8 Vihinen, 2009, Circulating adiponectin as a marker for glucocorticoid-related side effects in children and adolescents with inflammatory bowel disease, J Pediatr Gastroenterol Nutr, 48, 504, 10.1097/MPG.0b013e318186c495 Sidoroff, 2012, Glucocorticoid sensitivity in inflammatory bowel disease, Ann Med, 44, 578, 10.3109/07853890.2011.590521 Thia, 2009, Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study, Inflamm Bowel Dis, 15, 17, 10.1002/ibd.20608 Khan, 2011, Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis, Am J Gastroenterol, 106, 661, 10.1038/ajg.2011.72 Bermejo, 2012, Efficacy of different therapeutic options for spontaneous abdominal abscesses in Crohn's disease: are antibiotics enough?, Inflamm Bowel Dis, 18, 1509, 10.1002/ibd.21865 Ursing, 1982, A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden, II. Result. Gastroenterology, 83, 550, 10.1016/S0016-5085(82)80189-3 Colombel, 1999, A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease, Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol, 94, 674 Borgaonkar, 2000, A meta-analysis of antimycobacterial therapy for Crohn's disease, Am J Gastroenterol, 95, 725, 10.1111/j.1572-0241.2000.01842.x Feller, 2010, Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials, Clin Infect Dis, 50, 473, 10.1086/649923 Levine, 2011, Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease, J Crohns Colitis, 5, 222, 10.1016/j.crohns.2011.01.006 Muniyappa, 2009, Use and safety of rifaximin in children with inflammatory bowel disease, J Pediatr Gastroenterol Nutr, 49, 400, 10.1097/MPG.0b013e3181a0d269 Barabino, 2002, Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey, Aliment Pharmacol Ther, 16, 1125, 10.1046/j.1365-2036.2002.01269.x Jaspers, 2006, Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease, Inflamm Bowel Dis, 12, 831, 10.1097/01.mib.0000232470.00703.67 Riello, 2011, Tolerance and efficacy of azathioprine in pediatric Crohn's disease, Inflamm Bowel Dis, 17, 2138, 10.1002/ibd.21612 Punati, 2008, Effect of early immunomodulator use in moderate to severe pediatric Crohn disease, Inflamm Bowel Dis, 14, 949, 10.1002/ibd.20412 Prefontaine, 2009, Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, 1, Cd000067 Willoughby, 1971, Controlled trial of azathioprine in Crohn's disease, Lancet, 2, 944, 10.1016/S0140-6736(71)90268-6 Rosenberg, 1975, A controlled trial of azathioprine in Crohn's disease, Am J Dig Dis, 20, 721, 10.1007/BF01070829 O’Donoghue, 1978, Double-blind withdrawal trial of azathio-prine as maintenance treatment for Crohn's disease, Lancet, 2, 955, 10.1016/S0140-6736(78)92524-2 Summers, 1979, National Cooperative Crohn's Disease Study: results of drug treatment, Gastroenterology, 77, 847, 10.1016/0016-5085(79)90385-8 Candy, 1995, A controlled double blind study of azathioprine in the manage-ment of Crohn's disease, Gut, 37, 674, 10.1136/gut.37.5.674 Lemann, 2005, A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine, Gastroenterology, 128, 1812, 10.1053/j.gastro.2005.03.031 D’Haens, 2008, Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial, Gastroenterology, 135, 1123, 10.1053/j.gastro.2008.07.010 Hanauer, 2004, Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial, Gastroenterology, 127, 723, 10.1053/j.gastro.2004.06.002 Ramadas, 2010, Natural history of Crohn's disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates, Gut, 59, 1200, 10.1136/gut.2009.202101 Peyrin-Biroulet, 2011, Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease, Gut, 60, 930, 10.1136/gut.2010.227884 Cleynen, 2013, Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project, Gut, 62, 1556, 10.1136/gutjnl-2011-300777 Cosnes, 2013, Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial, Gastroenterology, 145, 758, 10.1053/j.gastro.2013.04.048 Panes, 2013, Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease, Gastroenterology, 145, 766, 10.1053/j.gastro.2013.06.009 Fuentes, 2003, High-dose azathioprine in children with inflammatory bowel disease, Aliment Pharmacol Ther, 17, 913, 10.1046/j.1365-2036.2003.01540.x D'Haens, 1999, Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine, Gastrointest Endosc, 50, 667, 10.1016/S0016-5107(99)80017-0 Colombel, 2010, Infliximab, azathioprine, or combination therapy for Crohn's disease, N Engl J Med, 362, 1383, 10.1056/NEJMoa0904492 Gearry, 2004, Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease, Pharmacoepidemiol Drug Saf, 13, 563, 10.1002/pds.926 Hindorf, 2006, Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease, Aliment Pharmacol Ther, 24, 331, 10.1111/j.1365-2036.2006.02977.x Kirschner, 1998, Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease, Gastroenterology, 115, 813, 10.1016/S0016-5085(98)70251-3 Lichtenstein, 2012, Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry, Am J Gastroenterol, 107, 1409, 10.1038/ajg.2012.218 Baldassano, 2013, 41 serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: develop registry data, Gastroenterology, 144, S-11, 10.1016/S0016-5085(13)60037-2 Ledder, 2013, Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease?, J Pediatr Gastroenterol Nutr, 57, 583, 10.1097/MPG.0b013e31829f16fc Dubinsky, 2002, 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease, Gastroenterology, 122, 904, 10.1053/gast.2002.32420 Ansari, 2002, Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease, Aliment Pharmacol Ther, 16, 1743, 10.1046/j.1365-2036.2002.01353.x Benkov, 2013, Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD, J Pediatr Gastroenterol Nutr, 56, 333, 10.1097/MPG.0b013e3182844705 Dubinsky, 2005, A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine, Am J Gastroenterol, 100, 2239, 10.1111/j.1572-0241.2005.41900.x Priest, 2006, Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease, Pharmacoeconomics, 24, 767, 10.2165/00019053-200624080-00004 Winter, 2004, Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease, Aliment Pharmacol Ther, 20, 593, 10.1111/j.1365-2036.2004.02124.x Dubinsky, 2000, Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease, Gastroenterology, 118, 705, 10.1016/S0016-5085(00)70140-5 Osterman, 2006, Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis, Gastroenterology, 130, 1047, 10.1053/j.gastro.2006.01.046 Rahhal, 2008, Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease, Inflamm Bowel Dis, 14, 1678, 10.1002/ibd.20522 Gerich, 2010, A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine, J Crohns Colitis, 4, 546, 10.1016/j.crohns.2010.03.004 Shih, 2012, Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism, Aliment Pharmacol Ther, 36, 449, 10.1111/j.1365-2036.2012.05206.x Lennard, 1987, Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells, J Chromatogr, 423, 169, 10.1016/0378-4347(87)80340-7 Dervieux, 1998, Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC, Clin Chem, 44, 551, 10.1093/clinchem/44.3.551 Kandiel, 2005, Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine, Gut, 54, 1121, 10.1136/gut.2004.049460 Camus, 2013, Long-term outcome of patients with Crohn's disease who respond to azathioprine, Clin Gastroenterol Hepatol, 11, 389, 10.1016/j.cgh.2012.10.038 Ashworth, 2012, Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort, Inflamm Bowel Dis, 18, 838, 10.1002/ibd.21844 Colletti, 2013, 833 malignancies in children receiving infliximab and other inflammatory bowel disease therapies: an inflammatory bowel disease multicenter, prospective, long-term registry of pediatric patients (develop) registry data, Gastroenterology, 144, 147, 10.1016/S0016-5085(13)60528-4 Kotlyar, 2011, A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease, Clin Gastroenterol Hepatol, 9, e1, 10.1016/j.cgh.2010.09.016 Peyrin-Biroulet, 2011, Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease, Gastroenterology, 141, 1621, 10.1053/j.gastro.2011.06.050 Singh, 2011, Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease, Gastroenterology, 141, 1612, 10.1053/j.gastro.2011.07.039 van Schaik, 2012, Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease, Gut, 61, 235, 10.1136/gut.2011.237412 Turner, 2007, Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease, Am J Gastroenterol, 102, 2804, 10.1111/j.1572-0241.2007.01474.x Uhlen, 2006, Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study, Inflamm Bowel Dis, 12, 1053, 10.1097/01.mib.0000235103.47280.bb Boyle, 2010, A single-center experience with methotrexate after thiopurine therapy in pediatric Crohn disease, J Pediatr Gastroenterol Nutr, 51, 714, 10.1097/MPG.0b013e3181dd861a Mack, 1998, Methotrexate in patients with Crohn's disease after 6-mercaptopurine, J Pediatr, 132, 830, 10.1016/S0022-3476(98)70313-0 Ravikumara, 2007, Role of methotrexate in the management of Crohn disease, J Pediatr Gastroenterol Nutr, 44, 427, 10.1097/MPG.0b013e3180320689 Weiss, 2009, Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues, J Pediatr Gastroenterol Nutr, 48, 526, 10.1097/MPG.0b013e318196df3e Willot, 2011, Methotrexate in the treatment of inflammatory bowel disease: an 8-year retrospective study in a Canadian pediatric IBD center, Inflamm Bowel Dis, 17, 2521, 10.1002/ibd.21653 Alfadhli, 2005, Methotrexate for induction of remission in refractory Crohn's disease, Cochrane Database Syst Rev, 1, Cd003459 Patel, 2009, Methotrexate for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, 4, Cd006884 Nathan, 2008, A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration, J Gastroenterol Hepatol, 23, 954, 10.1111/j.1440-1746.2007.05006.x Hashkes, 2014, Methotrexate: new uses for an old drug, J Pediatr, 164, 231, 10.1016/j.jpeds.2013.10.029 Kempinska, 2011, Short-course ondansetron for the prevention of methotrexate-induced nausea in children with Crohn disease, J Pediatr Gastroenterol Nutr, 53, 389, 10.1097/MPG.0b013e31822855e7 Valentino, 2014, Hepatotoxicity caused by methotrexate therapy in children with inflammatory bowel disease: a systematic review and meta-analysis, Inflamm Bowel Dis, 20, 47, 10.1097/01.MIB.0000436953.88522.3e Hyams, 2007, Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children, Gastroenterology, 132, 863, 10.1053/j.gastro.2006.12.003 Ruemmele, 2009, Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy, Inflamm Bowel Dis, 15, 388, 10.1002/ibd.20788 Hyams, 2000, Use of infliximab in the treatment of Crohn's disease in children and adolescents, J Pediatr, 137, 192, 10.1067/mpd.2000.107161 Kugathasan, 2000, Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease, Am J Gastroenterol, 95, 3189, 10.1111/j.1572-0241.2000.03263.x Baldassano, 2003, Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease, Am J Gastroenterol, 98, 833, 10.1111/j.1572-0241.2003.07343.x Cezard, 2003, A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease, J Pediatr Gastroenterol Nutr, 36, 632, 10.1097/00005176-200305000-00007 Lionetti, 2003, Response to infliximab is related to disease duration in paediatric Crohn's disease, Aliment Pharmacol Ther, 18, 425, 10.1046/j.1365-2036.2003.01672.x Borrelli, 2004, Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease, Dig Liver Dis, 36, 342, 10.1016/j.dld.2003.12.014 Afzal, 2007, Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease, Dig Dis Sci, 52, 3329, 10.1007/s10620-007-8102-1 Wynands, 2008, 12-month follow-up after successful infliximab therapy in pediatric crohn disease, J Pediatr Gastroenterol Nutr, 46, 293, 10.1097/MPG.0b013e31815604cd Ford, 2011, Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis, Am J Gastroenterol, 106, 644, 10.1038/ajg.2011.73 Hyams, 2012, Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children, Gastroenterology, 143, 365, 10.1053/j.gastro.2012.04.046 Rosh, 2009, Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease, Am J Gastroenterol, 104, 3042, 10.1038/ajg.2009.493 Russell, 2011, A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease, Aliment Pharmacol Ther, 33, 946, 10.1111/j.1365-2036.2011.04603.x Hanauer, 2006, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial, Gastroenterology, 130, 323, 10.1053/j.gastro.2005.11.030 Sandborn, 2007, Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial, Ann Intern Med, 146, 829, 10.7326/0003-4819-146-12-200706190-00159 de Ridder, 2004, Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands, J Pediatr Gastroenterol Nutr, 39, 46, 10.1097/00005176-200407000-00010 Crandall, 2009, Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH, J Pediatr Gastroenterol Nutr, 49, 183, 10.1097/MPG.0b013e3181a70f21 Teitelbaum, 2007, Infliximab in pediatric Crohn disease patients with enterovesicular fistulas, J Pediatr Gastroenterol Nutr, 44, 279, 10.1097/01.mpg.0000237933.38223.da Afzal, 2010, Recognition and treatment of genitourinary complications in paediatric Crohn's disease using infliximab, Acta Paediatr, 99, 1042, 10.1111/j.1651-2227.2010.01731.x Present, 1999, Infliximab for the treatment of fistulas in patients with Crohn's disease, N Engl J Med, 340, 1398, 10.1056/NEJM199905063401804 Panaccione, 2011, Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial, Can J Gastroenterol, 25, 419, 10.1155/2011/724813 Dewint, 2014, Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI), Gut, 63, 292, 10.1136/gutjnl-2013-304488 Hyams, 2011, Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension, Curr Med Res Opin, 27, 651, 10.1185/03007995.2010.547575 Lamireau, 2004, Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease, Inflamm Bowel Dis, 10, 745, 10.1097/00054725-200411000-00008 Barrie, 2007, Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease, Inflamm Bowel Dis, 13, 1424, 10.1002/ibd.20196 Kugathasan, 2003, Dermatologic manifestations of Crohn disease in children: response to infliximab, J Pediatr Gastroenterol Nutr, 37, 150, 10.1097/00005176-200308000-00013 Escher, 2002, Successful treatment of metastatic Crohn disease with infliximab, J Pediatr Gastroenterol Nutr, 34, 420, 10.1097/00005176-200204000-00021 Krishnan, 2006, Lung lesions in children with Crohn's disease presenting as nonresolving pneumonias and response to infliximab therapy, Pediatrics, 117, 1440, 10.1542/peds.2005-1559 Silbermintz, 2006, Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab, J Pediatr Gastroenterol Nutr, 42, 324, 10.1097/01.mpg.0000189347.32796.c5 Carpenter, 2004, Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab, J Pediatr, 144, 541, 10.1016/j.jpeds.2003.12.038 Lichtenstein, 2002, Infliximab improves quality of life in patients with Crohn's disease, Inflamm Bowel Dis, 8, 237, 10.1097/00054725-200207000-00001 DeBoer, 2012, Changes in inflammation and QoL after a single dose of infliximab during ongoing IBD treatment, J Pediatr Gastroenterol Nutr, 54, 486, 10.1097/MPG.0b013e3182382ee3 Malik, 2012, The effects of anti-TNF-alpha treatment with adalimumab on growth in children with Crohn's disease (CD), J Crohns Colitis, 6, 337, 10.1016/j.crohns.2011.09.004 Ryan, 2004, Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study, Aliment Pharmacol Ther, 20, 851, 10.1111/j.1365-2036.2004.02097.x Franchimont, 2004, Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease, Aliment Pharmacol Ther, 20, 607, 10.1111/j.1365-2036.2004.02152.x Thayu, 2008, Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study, Clin Gastroenterol Hepatol, 6, 1378, 10.1016/j.cgh.2008.07.010 Miheller, 2012, Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?, Expert Opin Biol Ther, 12, 179, 10.1517/14712598.2012.644271 Vande Casteele, 2012, Results on the optimisation phase of the prospective controlled trough level adapted infliximab treatment (TAXIT) trial, Gastroenterology, 142, 211, 10.1016/S0016-5085(12)60792-6 Steenholdt, 2014, Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial, Gut, 63, 919, 10.1136/gutjnl-2013-305279 Hanauer, 2002, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, Lancet, 359, 1541, 10.1016/S0140-6736(02)08512-4 Colombel, 2007, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial, Gastroenterology, 132, 52, 10.1053/j.gastro.2006.11.041 Schnitzler, 2009, Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort, Gut, 58, 492, 10.1136/gut.2008.155812 Armuzzi, 2013, Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission, Inflamm Bowel Dis, 19, 1065, 10.1097/MIB.0b013e3182802909 Sprakes, 2012, Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience, J Crohns Colitis, 6, 143, 10.1016/j.crohns.2011.07.011 Van Assche, 2008, Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial, Gastroenterology, 134, 1861, 10.1053/j.gastro.2008.03.004 Vande Casteele, 2013, Antibody response to infliximab and its impact on pharmacokinetics can be transient, Am J Gastroenterol, 108, 962, 10.1038/ajg.2013.12 Jones, 2013, Impact of concomitant immunomodulator treatment on efficacy and safety of anti-TNF therapy in Crohn's disease: a meta-analysis of placebo controlled trials with individual patient-level data, Gastroenterology, 144, S179, 10.1016/S0016-5085(13)60637-X Kierkus, 2013, P525 Efficacy infliximab with immunomodulator and infliximab alone of maintenance therapy in children with Crohn's disease — multicenter randomized study, J Crohn's Colitis, 7, 220, 10.1016/S1873-9946(13)60546-2 Cucchiara, 2009, Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies?, J Pediatr Gastroenterol Nutr, 48, 257, 10.1097/MPG.0b013e31818cf555 Feagan, 2014, Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease, Gastroenterology, 146, 681, 10.1053/j.gastro.2013.11.024 Reenaers, 2012, Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?, Aliment Pharmacol Ther, 36, 1040, 10.1111/apt.12076 Kestens, 2013, Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-alpha agents, Clin Gastroenterol Hepatol, 11, 826, 10.1016/j.cgh.2013.01.012 Hyams, 2009, Long-term outcome of maintenance infliximab therapy in children with Crohn's disease, Inflamm Bowel Dis, 15, 816, 10.1002/ibd.20845 Baert, 2003, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease, N Engl J Med, 348, 601, 10.1056/NEJMoa020888 Miele, 2004, Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab, J Pediatr Gastroenterol Nutr, 38, 502, 10.1097/00005176-200405000-00008 Candon, 2006, Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease, Clin Immunol, 118, 11, 10.1016/j.clim.2005.07.010 Lee, 2012, Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis, Eur J Gastroenterol Hepatol, 24, 1078, 10.1097/MEG.0b013e32835558cf Wewer, 2006, Infliximab dependency in a national cohort of children with Crohn's disease, J Pediatr Gastroenterol Nutr, 42, 40, 10.1097/01.mpg.0000189137.06151.33 de Ridder, 2008, Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort, Inflamm Bowel Dis, 14, 353, 10.1002/ibd.20329 Stephens, 2003, Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center, Am J Gastroenterol, 98, 104, 10.1111/j.1572-0241.2003.07161.x Jacobstein, 2005, Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium, Inflamm Bowel Dis, 11, 442, 10.1097/01.MIB.0000158166.88238.ea Crandall, 2003, Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model, Aliment Pharmacol Ther, 17, 75, 10.1046/j.1365-2036.2003.01411.x Friesen, 2004, Safety of infliximab treatment in pediatric patients with inflammatory bowel disease, J Pediatr Gastroenterol Nutr, 39, 265, 10.1097/00005176-200409000-00008 Kugathasan, 2002, Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction, Am J Gastroenterol, 97, 1408, 10.1111/j.1572-0241.2002.05784.x Lahdenne, 2010, Prevention of acute adverse events related to infliximab infusions in pediatric patients, Arthritis Care Res, 62, 785, 10.1002/acr.20246 Kolho, 2007, Severe adverse reactions to infliximab therapy are common in young children with inflammatory bowel disease, Acta Paediatr, 96, 128, 10.1111/j.1651-2227.2007.00042.x Hamalainen, 2012, Prevention of infusion reactions to infliximab in paediatric patients with oral acetylsalicylic acid, Clin Exp Rheumatol, 30, 590 Fidder, 2009, Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study, Gut, 58, 501, 10.1136/gut.2008.163642 de Bie, 2012, Antitumor necrosis factor treatment for pediatric inflammatory bowel disease, Inflamm Bowel Dis, 18, 985, 10.1002/ibd.21871 Rahier, 2009, European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, J Crohns Colitis, 3, 47, 10.1016/j.crohns.2009.02.010 Veereman-Wauters, 2012, Risk of infection and prevention in pediatric patients with IBD, J Pediatr Gastroenterol Nutr, 54, 830, 10.1097/MPG.0b013e31824d1438 Mackey, 2009, Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update, J Pediatr Gastroenterol Nutr, 48, 386, 10.1097/MPG.0b013e3181957a11 Parakkal, 2011, Hepatosplenic T-cell lymphoma in patients receiving TNF-alpha inhibitor therapy: expanding the groups at risk, Eur J Gastroenterol Hepatol, 23, 1150, 10.1097/MEG.0b013e32834bb90a Sokol, 2009, Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle, Gut, 58, 1427, 10.1136/gut.2009.181982 Diak, 2010, Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration, Arthritis Rheum, 62, 2517, 10.1002/art.27511 Kwon, 2003, Case reports of heart failure after therapy with a tumor necrosis factor antagonist, Ann Intern Med, 138, 807, 10.7326/0003-4819-138-10-200305200-00008 Haddock, 2011, A case of posterior reversible encephalopathy syndrome in a child with Crohn's disease treated with Infliximab, J Crohns Colitis, 5, 623, 10.1016/j.crohns.2011.06.011 Hiremath, 2011, Infliximab-induced psoriasis in children with inflammatory bowel disease, J Pediatr Gastroenterol Nutr, 52, 230, 10.1097/MPG.0b013e3181f3d9ab De Bie, 2011, The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited, Aliment Pharmacol Ther, 33, 243, 10.1111/j.1365-2036.2010.04507.x Katz, 2012, Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response, Inflamm Bowel Dis, 18, 2026, 10.1002/ibd.22902 Kopylov, 2011, The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab, Aliment Pharmacol Ther, 33, 349, 10.1111/j.1365-2036.2010.04523.x Regueiro, 2007, Infliximab dose intensification in Crohn's disease, Inflamm Bowel Dis, 13, 1093, 10.1002/ibd.20177 Sandborn, 2011, Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics, Inflamm Bowel Dis, 17, 141, 10.1002/ibd.21328 Pariente, 2012, Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease, Inflamm Bowel Dis, 18, 1199, 10.1002/ibd.21839 Ben-Horin, 2013, Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease, Clin Gastroenterol Hepatol, 11, 444, 10.1016/j.cgh.2012.10.020 Karmiris, 2009, Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease, Gastroenterology, 137, 1628, 10.1053/j.gastro.2009.07.062 Lazzerini, 2013, Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial, JAMA, 310, 2164, 10.1001/jama.2013.280777 Felipez, 2012, Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab, J Pediatr Gastroenterol Nutr, 54, 28, 10.1097/MPG.0b013e318228349e Lazzerini, 2007, Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results, Aliment Pharmacol Ther, 25, 419, 10.1111/j.1365-2036.2006.03211.x Gisbert, 2010, Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding, Inflamm Bowel Dis, 16, 881, 10.1002/ibd.21154 Griffiths, 1993, Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease, J Pediatr Gastroenterol Nutr, 17, 186, 10.1097/00005176-199308000-00010 Cezard, 2009, Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial, Gastroenterol Clin Biol, 33, 31, 10.1016/j.gcb.2008.07.007 Tolia, 1989, Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience, J Pediatr Gastroenterol Nutr, 8, 333, 10.1097/00005176-198904000-00012 Christensen, 1993, Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children, Dig Dis Sci, 38, 1831, 10.1007/BF01296106 Wiersma, 2004, Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease, Inflamm Bowel Dis, 10, 626, 10.1097/00054725-200409000-00019 Wilschanski, 1996, Supplementary enteral nutrition maintains remission in paediatric Crohn's disease, Gut, 38, 543, 10.1136/gut.38.4.543 Belli, 1988, Chronic intermittent elemental diet improves growth failure in children with Crohn's disease, Gastroenterology, 94, 603, 10.1016/0016-5085(88)90230-2 Takagi, 2006, Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn's disease: a randomized-controlled trial, Aliment Pharmacol Ther, 24, 1333, 10.1111/j.1365-2036.2006.03120.x Yamamoto, 2010, Enteral nutrition for the maintenance of remission in Crohn's disease: a systematic review, Eur J Gastroenterol Hepatol, 22, 1, 10.1097/MEG.0b013e32832c788c Turner, 2011, Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses, Inflamm Bowel Dis, 17, 336, 10.1002/ibd.21374 Feagan, 2008, Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials, JAMA, 299, 1690, 10.1001/jama.299.14.1690 Rolfe, 2006, Probiotics for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, 4, Cd004826 Renna, 2008, Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease, Gastroenterology, 135, 1500, 10.1053/j.gastro.2008.07.066 Blum, 2009, Postoperative therapy for Crohn's disease, Inflamm Bowel Dis, 15, 463, 10.1002/ibd.20741 Pascua, 2008, Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn's disease, Aliment Pharmacol Ther, 28, 545, 10.1111/j.1365-2036.2008.03774.x Doherty, 2009, Interventions for prevention of post-operative recurrence of Crohn's disease, Cochrane Database Syst Rev, 4, Cd006873 Peyrin-Biroulet, 2009, Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis, Am J Gastroenterol, 104, 2089, 10.1038/ajg.2009.301 Gordon, 2011, Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease, Cochrane Database Syst Rev, 1, Cd008414 Regueiro, 2011, Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease, Dig Dis Sci, 56, 3610, 10.1007/s10620-011-1785-9 De Cruz, 2013, Optimising post-operative Crohn's disease management: best drug therapy alone versus colonoscopic monitoring with treatment step-up. the POCER study, Gastroenterology, 144, 164, 10.1016/S0016-5085(13)60588-0 Doherty, 2010, Meta-analysis: targeting the intestinal microbiota in prophylaxis for postoperative Crohn's disease, Aliment Pharmacol Ther, 31, 802 Yamamoto, 2010, Prevention of recurrence after surgery for Crohn's disease: efficacy of infliximab, World J Gastroenterol, 16, 5405, 10.3748/wjg.v16.i43.5405 Vasseur, 2010, Nutritional status and growth in pediatric Crohn's disease: a population-based study, Am J Gastroenterol, 105, 1893, 10.1038/ajg.2010.20 Froslie, 2007, Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort, Gastroenterology, 133, 412, 10.1053/j.gastro.2007.05.051 Kim, 1999, Optimum duration of treatment with 6-mercaptopurine for Crohn's disease, Am J Gastroenterol, 94, 3254, 10.1111/j.1572-0241.1999.01532.x Bouhnik, 1996, Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine, Lancet, 347, 215, 10.1016/S0140-6736(96)90402-X Mantzaris, 2007, The long-term efficacy of azathioprine does not wane after four years of continuous treatment in patients with steroid-dependent luminal Crohn's disease, J Crohns Colitis, 1, 28, 10.1016/j.crohns.2007.06.002 Treton, 2009, Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse, Clin Gastroenterol Hepatol, 7, 80, 10.1016/j.cgh.2008.08.028 Clarke, 2012, Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission, Inflamm Bowel Dis, 18, 174, 10.1002/ibd.21792 Fraser, 2002, The efficacy of methotrexate for maintaining remission in inflammatory bowel disease, Aliment Pharmacol Ther, 16, 693, 10.1046/j.1365-2036.2002.01227.x Olivieri, 2013, Can we reduce the dosage of biologics in spondyloarthritis?, Autoimmun Rev, 12, 691, 10.1016/j.autrev.2012.08.013 Oussalah, 2010, Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy, Am J Gastroenterol, 105, 1142, 10.1038/ajg.2010.158 Louis, 2012, Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped, Gastroenterology, 142, 63, 10.1053/j.gastro.2011.09.034 Waugh, 2010, Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort, Aliment Pharmacol Ther, 32, 1129, 10.1111/j.1365-2036.2010.04446.x